About: Efficacy of remdesivir in COVID-19 patients with a simulated two-arm controlled study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Efficacy of remdesivir in COVID-19 patients with a simulated two-arm controlled study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Efficacy of remdesivir in COVID-19 patients with a simulated two-arm controlled study
Creator	Chen, Hsiu-Hsi Hsu, Chen-Yang Lai, Chao-Chih Yen, Ming-Fang Li, Sam Chen, -Sheng
Source	MedRxiv
abstract	While the recent study on the compassionate use of remdesivir for COVID-19 patients has shown a 68% clinical improvement7 it is a one-arm study that renders the evaluation of the efficacy in reducing death and the length of stay of hospitalization intractable due to a lacking of the control group. We came up with a two-arm controlled study design to simulate the treated and the untreated (control group) group by applying two respective transition models to the empirical data on dynamics of the disease severity (Figure 2 of the original article7) that are classified into low- (no and low oxygen supplement), medium- (non-invasive ventilator and high oxygen supplement), and high-(ECMO and invasive ventilator) from enrolment until discharge, death or the end of follow-up. By using a simulated two-arm controlled study, the remdesivir treatment group as opposed to the control group led to a statistically significantly 29% (95% CI: 22-35%) reduction of death from COVID-19. The treated group also revealed a 33% (95% CI 28-38%) significantly higher odds of discharge than the control group. The median time to discharge for the treated group (5.5 days, 16.5 days, and 29.5 days for low-, medium-, and high-risk state, respectively) was around half of those of the control arm. Our results with a simulated two-arm controlled study have not only corroborated the efficacy of remdesivir but also made great contribution to designing a further large-scale randomized controlled trial. They have significant implications for reducing transmission probability and infectious time of COVID-19 patients when contacting with susceptible health care workers during hospitalization.
has issue date	2020-05-08(xsd:dateTime)
bibo:doi	10.1101/2020.05.02.20088559
has license	medrxiv
sha1sum (hex)	4af0bf18efc88b3a5339b04bda49def8d5a06f4a
schema:url	https://doi.org/10.1101/2020.05.02.20088559
resource representing a document's title	Efficacy of remdesivir in COVID-19 patients with a simulated two-arm controlled study
resource representing a document's body	covid:4af0bf18efc88b3a5339b04bda49def8d5a06f4a#body_text
is schema:about of	covid:arg/4af0bf18efc88b3a5339b04bda49def8d5a06f4a named entity 'remdesivir' named entity 'remdesivir' named entity 'prophylactic' named entity 'Markov model' named entity 'preprint' named entity 'medRxiv' named entity 'credible interval' named entity 'Monte Carlo' named entity 'preprint' named entity '95%' named entity 'preprint' named entity 'controlled study' named entity 'controlled study' named entity 'COVID-19' named entity 'COVID-19' named entity 'COVID-19' named entity 'CC-BY-NC-ND 4.0' named entity 'study design' named entity 'controlled study' named entity 'remdesivir' named entity 'control group' named entity 'oxygen' named entity 'controlled study' named entity 'non-invasive ventilator' named entity 'non-invasive ventilator' named entity 'probability' named entity 'ECMO' named entity 'preprint' named entity 'oxygen' named entity 'remdesivir' named entity 'medRxiv' named entity 'remdesivir' named entity 'high-risk' named entity 'treatment group' named entity 'follow-up' named entity '95% CI' named entity 'medRxiv' named entity 'statistically significantly' named entity 'preprint' named entity 'risk of death' named entity 'controlled study' named entity 'remdesivir' named entity '95% CI' named entity 'remdesivir' named entity 'COVID-19' named entity 'follow-up' named entity 'randomized controlled trial' named entity 'remdesivir' named entity 'COVID-19' named entity 'anti-viral therapy' named entity 'empirical data' named entity '95% CI' named entity 'treatment groups' named entity 'medRxiv' named entity 'continuous-time' named entity 'CC-BY-NC-ND 4.0' named entity 'preprint' named entity '5.5' named entity '95% CI' named entity 'control group' named entity 'high-risk' named entity '95% CI' named entity 'relative risk' named entity 'probability' named entity 'influenza' named entity 'medRxiv' named entity 'control group' named entity 'randomized controlled trial' named entity 'controlled study' named entity 'high-risk' named entity 'peer review' named entity 'remdesivir' named entity 'preprint' named entity 'control group' named entity 'randomized controlled trial' named entity 'COVID-19' named entity 'COVID-19' named entity 'COVID-19 pandemic' named entity 'preprint'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software